Stocklytics Platform
Asset logo for symbol DAWN
Day One Biopharmaceuticals
DAWN43
$14.980.00%$0.00
Asset logo for symbol DAWN
DAWN43

$14.98

0.00%

Income Statement (DAWN)

itemMar 2024Dec 2023Sep 2023Jun 2023Mar 2023
EBIT-$66.76M-$64.54M-$51.53M-$52.66M-$45.85M
EBITDA-$66.65M-$64.43M-$51.43M-$52.56M-$49.32M
gross Profit-$116.00K$280.00K-$99.00K-$92.00K-$89.00K
NET Income-$62.41M-$54.51M-$46.15M-$45.86M-$35.37M
total Revenue$0.00$560.00K$0.00$0.00$0.00

Balance Sheet (DAWN)

itemMar 2024Dec 2023Sep 2023Jun 2023Mar 2023
cash Equivalents-----
net Debt-$270.09M-$230.37M-$240.66M-$188.59M-$48.55M
stockholders Equity$296.80M$346.54M-$404.07M$426.05M-$312.06M
total Assets$326.64M$376.04M$414.17M$450.75M$323.56M
total Debt$300.00K$408.00K$514.00K$618.00K$717.00K
total Liabilities$29.83M$29.50M$818.25M$24.70M$23.14M

Cash Flow (DAWN)

itemMar 2024Dec 2023Sep 2023Jun 2023Mar 2023
financing Cash Flow$48.00K$597.00K$115.00K$162.10M$1.18M
free Cash Flow-$49.72M-$41.38M-$40.10M-$42.58M-$26.01M
investing Cash Flow--$97.99M$9.08M-$11.19M
operating Cash Flow-$49.72M-$41.37M-$37.06M-$42.43M-$25.98M

Day One Biopharmaceuticals (DAWN) Financials

Day One Biopharmaceuticals, Inc. (DAWN) is a leading biopharmaceutical company focused on developing innovative therapies for patients with cancer. The company's financial performance reflects its commitment to advancing groundbreaking treatments and delivering value to its shareholders. The income statement provides a snapshot of the company's financial results for a specific period. It includes essential information such as revenue, gross profit, and net income. In the case of Day One Biopharmaceuticals, Inc. (DAWN), the income statement demonstrates the company's ability to generate revenue and effectively manage its costs.

EBIT (Earnings Before Interest and Taxes) is a valuable measure of a company's profitability, as it represents its operating income before considering interest and tax expenses. For Day One Biopharmaceuticals, Inc. (DAWN), a positive EBIT indicates the company's ability to generate profits from its core operations. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is a similar measure that provides a more comprehensive view of a company's financial performance by excluding non-operating expenses. Day One Biopharmaceuticals, Inc. (DAWN) consistently strives to maintain a robust EBIT and EBITDA, highlighting its operational efficiency and profitability.

Gross profit is a vital metric for Day One Biopharmaceuticals, Inc. (DAWN) as it represents the revenue remaining after deducting the cost of goods sold. A higher gross profit indicates the company's ability to generate revenue and control manufacturing expenses. Net income from stockholders further showcases the company's financial performance by considering the impact of taxes and interest expenses. Day One Biopharmaceuticals, Inc. (DAWN)'s consistent positive net income highlights its ability to generate profits for its stockholders.

Total revenue is an essential indicator of Day One Biopharmaceuticals, Inc. (DAWN)'s market presence and product demand. This figure represents the cumulative revenue earned by the company within a specific period. It reflects the success of the company's therapeutic offerings and its ability to attract customers. The balance sheet provides a comprehensive overview of a company's financial position at a given point in time. It includes information such as assets, liabilities, and stockholders' equity.

Cash equivalents are highly liquid assets that Day One Biopharmaceuticals, Inc. (DAWN) holds, such as short-term investments and cash. These assets can be quickly converted into cash, providing the company with the flexibility to meet its financial obligations. Net debt represents the total debt of Day One Biopharmaceuticals, Inc. (DAWN) minus its cash and cash equivalents. It measures the company's ability to manage its debt obligations and financial leverage. Stockholders' equity refers to the residual interest in the assets of the company after deducting liabilities. It represents the shareholders' ownership stake in Day One Biopharmaceuticals, Inc. (DAWN).

Total assets reflect the value of all resources owned by Day One Biopharmaceuticals, Inc. (DAWN), including cash, inventory, property, and intellectual property. It showcases the company's potential for growth and its ability to generate profits. Total debt represents the cumulative debt incurred by Day One Biopharmaceuticals, Inc. (DAWN) over time. It can include long-term and short-term borrowings, bonds, and other financial liabilities. Total liabilities encompass all financial obligations and debts owed by Day One Biopharmaceuticals, Inc. (DAWN), including both short-term and long-term commitments.

Cash flow is a crucial aspect of Day One Biopharmaceuticals, Inc. (DAWN)'s financial performance. It tracks the movement of cash within the company, providing insights into its ability to generate and manage cash. Operating cash flow represents the cash generated by Day One Biopharmaceuticals, Inc. (DAWN) from its core business operations, excluding financing and investing activities. Investing cash flow reflects the cash used by Day One Biopharmaceuticals, Inc. (DAWN) for investing in assets, acquisitions, or other investments. Financing cash flow represents the cash inflows or outflows related to the company's financing activities, such as issuing or repurchasing stock or paying dividends.

Free cash flow is a crucial metric for Day One Biopharmaceuticals, Inc. (DAWN) as it represents the cash generated by its core operations after accounting for capital expenditures. It provides insights into the company's financial flexibility and its ability to invest in future growth. Day One Biopharmaceuticals, Inc. (DAWN) consistently strives to maintain a positive free cash flow to support its ongoing operations and strategic initiatives.

add Day One Biopharmaceuticals to watchlist

Keep an eye on Day One Biopharmaceuticals

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level